193 related articles for article (PubMed ID: 29173766)
1. Changing costs of metastatic non small cell lung cancer in the Netherlands.
Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
[TBL] [Abstract][Full Text] [Related]
2. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands.
Pompen M; Gok M; Novák A; van Wuijtswinkel R; Biesma B; Schramel F; Stigt J; Smit H; Postmus P
Lung Cancer; 2009 Apr; 64(1):110-6. PubMed ID: 18805601
[TBL] [Abstract][Full Text] [Related]
3. Costs of non-small cell lung cancer in the Netherlands.
van der Linden N; Bongers ML; Coupé VM; Smit EF; Groen HJ; Welling A; Schramel FM; Uyl-de Groot CA
Lung Cancer; 2016 Jan; 91():79-88. PubMed ID: 26589654
[TBL] [Abstract][Full Text] [Related]
4. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer.
Engel-Nitz NM; Johnson MP; Bunner SH; Ryan KJ
J Manag Care Spec Pharm; 2020 Jun; 26(6):729-740. PubMed ID: 32463768
[TBL] [Abstract][Full Text] [Related]
5. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
7. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
8. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.
Guérin A; Sasane M; Zhang J; Culver KW; Dea K; Nitulescu R; Wu EQ
J Med Econ; 2015 Apr; 18(4):312-22. PubMed ID: 25565443
[TBL] [Abstract][Full Text] [Related]
9. Metastatic non-small cell lung cancer: costs associated with disease progression.
Fox KM; Brooks JM; Kim J
Am J Manag Care; 2008 Sep; 14(9):565-71. PubMed ID: 18778171
[TBL] [Abstract][Full Text] [Related]
10. Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.
Naito T; Okayama T; Aoyama T; Ohashi T; Masuda Y; Kimura M; Shiozaki H; Murakami H; Kenmotsu H; Taira T; Ono A; Wakuda K; Imai H; Oyakawa T; Ishii T; Omori S; Nakashima K; Endo M; Omae K; Mori K; Yamamoto N; Tanuma A; Takahashi T
BMC Cancer; 2017 Nov; 17(1):800. PubMed ID: 29183277
[TBL] [Abstract][Full Text] [Related]
11. Management and costs of treating lung cancer patients in a university hospital.
Dedes KJ; Szucs TD; Bodis S; Joerger M; Lowy A; Russi EW; Steinert HC; Weder W; Stahel RA
Pharmacoeconomics; 2004; 22(7):435-44. PubMed ID: 15137882
[TBL] [Abstract][Full Text] [Related]
12. Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.
Ihbe-Heffinger A; Paessens BJ; von Schilling C; Shlaen M; Gottschalk N; Berger K; Bernard R; Kiechle M; Peschel C; Jacobs VR
Onkologie; 2011; 34(5):241-6. PubMed ID: 21577029
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
[TBL] [Abstract][Full Text] [Related]
15. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
16. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
Maslove L; Gower N; Spiro S; Rudd R; Stephens R; West P
Thorax; 2005 Jul; 60(7):564-9. PubMed ID: 15994264
[TBL] [Abstract][Full Text] [Related]
17. Costs for 5-year lung cancer survivors in a tertiary care hospital in South Korea.
Park YS; Kim SH; Park SK; Park BJ; Kim YT; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Shim YS; Yang SC
Lung Cancer; 2010 May; 68(2):299-304. PubMed ID: 19646776
[TBL] [Abstract][Full Text] [Related]
18. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
[TBL] [Abstract][Full Text] [Related]
19. Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.
Vera-Llonch M; Weycker D; Glass A; Gao S; Borker R; Barber B; Oster G
BMC Health Serv Res; 2011 Nov; 11():305. PubMed ID: 22074001
[TBL] [Abstract][Full Text] [Related]
20. An economic analysis of sublobar resection versus thermal ablation for early-stage non-small-cell lung cancer.
Kwan SW; Mortell KE; Hippe DS; Brunner MC
J Vasc Interv Radiol; 2014 Oct; 25(10):1558-64; quiz 1565. PubMed ID: 25130308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
